2024 Exhibitors Search
Epi Biotech Co., Ltd.
| Country | Korea, South |
|---|---|
| Address | |
| Tel (Rep.) | 070-4209-0556 |
| Website | http://epibiotech.com |
Company Introduction
Biotech specialized with hair loss treatments, possessing various modalities such as cell therapy, antibody drug, small molecule(synthetic drug), and etc. Over 10 years of hair loss resesarches and established proper lab infrastructure. Have patents for hair loss antibodies and personnel. We have received the first IND approval for Dermal Papilla Cell therapy and entering phase 1/2a. Also, creating the 'First-in-Class' antibody drug. Also, providing various CRO services with various animal models including alopecia areata model. We have hair follicle data from mouse/human with single cell analyzed database, which allows us to find hair loss related genes or mechanism of actions.
Promotional video
Exhibit Item
Biotech specialized with hair loss treatments, possessing various modalities such as cell therapy, antibody drug, small molecule(synthetic drugs,) and etc. We have received the first IND approval for Dermal Papilla Cell therapy and entering phase 1/2a. Also, developing the 'First-in-Class' antibody therapy, which would be the first antibody for androgenic alopecia. Related to controlling inflammation/immune response, it would be the ultimate treatment for intractable alopecia. Our small molecule drug, which is developed as topical treatment, has shown superior efficacy in female pattern hair loss compared to conventional treatments. Also, providing various CRO services with various animal models including alopecia areata model.
Exhibit Item Images
-
Product Name : Dermal Papilla Cell therapyDermal Papilla cell(DPC) has excellent hair growth efficacy. We have received the first IND approval for DPC cell therapy. We have secured our own patented DPC separation, culture, and culture media. It has shown excellent hair growth effect, superior to other cell therapies.
Exhibit Description
The first IND approval for Dermal Papilla Cell therapy and entering phase 1/2a. With our cultured method and media, separate the DP from the hair follicle then proliferate and mass-culture DP, which is injected back into the patient. Also being developed as allogenic cell therapy.
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.